You are here: Industry Insights > haemophilia

News List

Novo Nordisk resumes late-stage haemophilia trials pharmatimes
August 17, 2020
Novo Nordisk is set to resume the phase 3 clinical trials of concizumab in haemophilia A and B, with or without inhibitors, following a previous safety scare.
Regeneron and Intellia to develop new haemophilia therapies pharmaceutical-technology
June 03, 2020
Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.
Sobi releases new haemophilia treatment report pharmaceutical-technology
April 20, 2020
Biopharmaceutical firm Sobi has released the 2020 Haemophilia Index, a report that analyses the quality of life of patients treated for haemophilia in Europe.
Concizumab haemophilia trials paused over safety concerns europeanpharmaceuticalreview
March 19, 2020
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
Novo cancels haemophilia drug Phase III trial pharmatimes
March 18, 2020
Novo Nordisk has paused the Phase III explorer7 and explorer8 trials for haemophilia drug concizumab, due to non-fatal thrombotic events, the company says.
Novo Nordisk receives FDA nod for haemophilia A drug Esperoct pharmaceutical-technology
February 22, 2019
Danish Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for its drug Esperoct (turoctocog alfa pegol, N8-GP) indicated for haemophilia A treatment in both adults and children.....
No US launch until 2020 for Novo’s new haemophilia therapy pharmaphorum
February 21, 2019
The US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks to maintain its presence in an increasingly competitive sector of the drug market.
Bayer Inc. receives approval for hemophilia A treatment Jivi firstwordpharma
October 25, 2018
Bayer Inc. receives approval for hemophilia A treatment Jivi
Strong efficacy but serious side-effects with Spark's haemophilia drug drop shares by 30% pharmafile
August 09, 2018
Spark Therapeutics has been left reeling after it revealed new data on its haemophilia A treatment, which, while promising in efficacy, left investors disappointed and share price plummeting.
Shire and partners launch Irish haemophilia study pharmatimes
December 18, 2017
Shire, the Royal College of Surgeons Ireland (RCSI) and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, have initiated a new study that aims to better personalise the care of haemophilia patients.

Previous page 1 2 Next page